Showing 791-800 of 1564 results for "".
- AI Algorithms Can Determine How Well Newborns Nurse, Study Showshttps://reachmd.com/news/ai-algorithms-can-determine-how-well-newborns-nurse-study-shows/2462900/Is tongue-tie surgery needed? An estimated 7% of babies are diagnosed with a condition called tongue-tie, in which the connection between the tongue and the floor of the mouth is too strong and limits tongue movement. Th
- Study Reveals Low COVID-19 Transmission Rate from Mothers to Newbornshttps://reachmd.com/news/study-reveals-low-covid-19-transmission-rate-from-mothers-to-newborns/2462308/Annex A. Credit: KK Women's and Children's Hospital A
- Lockdowns Had an Impact on Gut Microbes and Allergies in Newborns, New Research Revealshttps://reachmd.com/news/lockdowns-had-an-impact-on-gut-microbes-and-allergies-in-newborns-new-research-reveals/2457388/Lockdowns imposed during the COVID-19 pandemic had an impact on the gut microbiome development of babies born during these periods according to new research from RCSI University of Medicine and Health Sciences, Children's Health Ireland and APC Microbiome Ireland (APC), a world leading SFI R
- New T Cell Subset Linked to Bone Loss in Rheumatoid Arthritis, Offering Novel Therapeutic Targethttps://reachmd.com/news/new-t-cell-subset-linked-to-bone-loss-in-rheumatoid-arthritis-offering-novel-therapeutic-target/2483864/A newly identified subset of regulatory T cells, known as iTr35 cells, may play a critical role in protecting against bone loss in patients with rheumatoid arthritis (RA), according to a p
- Immune Atlas at Cell Level Points to New Combination Treatment for Incurable Childhood Cancerhttps://reachmd.com/news/immune-atlas-at-cell-level-points-to-new-combination-treatment-for-incurable-childhood-cancer/2456755/Immune Atlas at Cell Level Points to New Combination Treatment for Incurable Childhood Cancer Immune Atlas at Cell Level Points to New Combination Treatment for Incurable Childhood Cancer Childhood cancer is a devastating diagnosis that affects thousands
- Advancing T Cell Therapies in Oncology: Precision, Safety, and Efficacyhttps://reachmd.com/news/advancing-t-cell-therapies-in-oncology-precision-safety-and-efficacy/2483337/In the evolving landscape of oncology, T cell therapies stand at the forefront of innovation, offering hope where traditional methods have struggled. These approaches promise tailored precision against malignancies, yet their clinical impact still depends on overcoming real-world co
- Healthcare Access for Sickle Cell Patients in Ghana: Challenges and Innovationshttps://reachmd.com/news/healthcare-access-for-sickle-cell-patients-in-ghana-challenges-and-innovations/2483106/Sickle cell disease (SCD) is reshaping Ghana’s healthcare priorities, as gaps in treatment access are widening disparities and driving avoidable crises—making systemic intervention increasingly urgent. While genotype can influence clinical course, the most immediate barriers in Ghana
- Respiratory Viruses and Dormant Cancer Cells: Unveiling the Hidden Threat of Relapsehttps://reachmd.com/news/respiratory-viruses-and-dormant-cancer-cells-unveiling-the-hidden-threat-of-relapse/2482964/The emerging intersection between respiratory viruses and cancer progression is posing a hidden threat. A key mechanism is involving the reactivation of dormant cancer cells, with the inflammatory mediator IL-6 playing a crucial role during infection. Infections by respiratory viruse
- Fucosyltransferase VII: A Hidden Player in Sickle Cell Disease Managementhttps://reachmd.com/news/fucosyltransferase-vii-a-hidden-player-in-sickle-cell-disease-management/2475794/Emerging evidence suggests Fucosyltransferase VII (FUT7), an enzyme central to selectin ligand biosynthesis, may be an underrecognized driver of vascular occlusion in sickle cell disease, with particularly profound implications in regions such as Nigeria where genetic modifiers shape clinic
- Combination Therapy and Outcomes in Childhood B-Cell Acute Lymphoblastic Leukemiahttps://reachmd.com/news/combination-therapy-and-outcomes-in-childhood-b-cell-acute-lymphoblastic-leukemia/2474731/Recent innovations in pediatric oncology reveal a dual-drug therapy developed by Cambridge researchers, representing a significant leap forward by reducing chemotherapy reliance while improving outcomes, notably in older pediatric B-cell acute lymphoblastic leukemia patient